Preclinical studies and drug combination of low-cost molecules for Chagas disease

Chagas disease is caused by the protozoan Trypanosoma cruzi (T. cruzi). It remains the major parasitic disease in Latin America and is spreading worldwide, affecting over 10 million people. Hundreds of new compounds with trypanosomicidal action have been identified from different sources such as syn...

תיאור מלא

מידע ביבליוגרפי

מחבר ראשי:	Aguilera, Elena (author)
מחברים אחרים:	Sánchez, Carina (author), Cruces, María Eugenia (author), Dávila Saralegui, Belén (author), Minini Rivas, Lucía (author), Mosquillo, María Florencia (author), Pérez-Díaz, Leticia (author), Serna, Elva (author), Torres, Susana (author), Schini, Alicia (author), Sanabria, Luis (author), Vera de Bilbao, N.I. (author), Yaluff, Gloria (author), Zolessi, Flavio R. (author), Ceilas, Luis Fabian (author), Cerecetto, Hugo (author), Álvarez, Guzmán (author)
פורמט:	article
שפה:	אנגלית
יצא לאור:	2023
נושאים:	Chagas disease Pre-clinically studied Drug combination RMN metabolomics
גישה מקוונת:	https://hdl.handle.net/20.500.12008/43097
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!